To view the PDF file, sign up for a MySharenet subscription.

LIFE HEALTHCARE GROUP HOLDINGS LIMITED - Changes to the board of directors and changes to the terms of reference for the nominations and governance committee

Release Date: 28/07/2022 11:10
Code(s): LHC LHC02 LHC01     PDF:  
Wrap Text
Changes to the board of directors and changes to the terms of reference for the nominations and governance committee

LIFE HEALTHCARE GROUP HOLDINGS LIMITED
(Incorporated in the Republic of South Africa)
(Registration number: 2003/002733/06)
ISIN: ZAE000145892
Share Code: LHC
(“the Company”)

LIFE HEALTHCARE FUNDING LIMITED
(Incorporated in the Republic of South Africa with limited liability under registration number
2016/273566/06)
Bond company code: LHFI
(“Life Healthcare Funding”)

CHANGES TO THE BOARD OF DIRECTORS AND CHANGES TO THE TERMS OF
REFERENCE FOR THE NOMINATIONS AND GOVERNANCE COMMITTEE

Board appointments
In keeping with the Board’s succession plan and strategy, the Company is pleased to
announce the appointments of Mr Lars Holmqvist and Dr Jeanne Bolger as independent non-
executive directors of the Board, with effect from 1 August 2022.

Lars has over 25 years’ experience in the sectors of health, pharmaceuticals, biotechnology
and medical diagnostics and is a former senior corporate executive in the global life sciences
sector. He has an accomplished portfolio as a non-executive director, with significant
experience in management, finance and sales and marketing, across international companies
and sectors. Lars currently chairs the Board of Biovica International AB, a Swedish based
cancer diagnostics company and he also serves as a non-executive director of Vitrolife AB,
H.Lundbeck AS and ALK Abello AS.

Lars’ previous executive roles included serving as President of Life Science & Diagnostic
Group at Agilent Technologies Inc, President & CEO of Dako AS and President International
for Applied Biosystems Inc. He also served as a Senior Advisor to Bain Capital Private Equity
and was a director at Tecan Group AG. Lars currently resides in Sweden.

Jeanne is a pharmaceutical physician with 35 years’ experience in leadership roles, spanning
commercial strategy, medical and regulatory affairs, business development and venture
investments. Jeanne joined Johnson and Johnson (J&J) Innovation – JJDC, the Corporate
Venture Fund of J&J in 2013. Prior to this, Jeanne had been Global Head of Scientific
Licensing in the Pharmaceuticals Business Development Group at Janssen, J&J. Over the
past nine years, Jeanne has advised on Seed, Series A, Series B and syndicated
biotechnology and diagnostics investments across therapy areas. She was a member of the
Investment Committee for investments in robotics, Big Data and Digital Health technologies.
Jeanne has served as a non-executive director on multiple J&J Investee company boards and
their Audit and Remuneration sub-committees.

Jeanne recently retired from her role as Vice President, Venture Investments at JJDC. She is
currently an independent non-executive Chair of a European Venture Capital-backed biotech
company and is a venture partner at a European Venture Capital Fund. She has also been
appointed to the Board of a new Translational Fund at the Sir Francis Crick Institute in London,
UK. Jeanne currently resides in Ireland.

Dr Victor Litlhakanyane, Chairman of the Board stated, “The Board is delighted to welcome
two accomplished international directors to our Board, as we continue to focus on our offshore
footprint. We have no doubt that their significant global experience in the healthcare sector
will add tremendous insight and value to the Company.”

Board committee changes
With effect from the date of their appointments, Lars will serve on the Investment and Audit
Committees to complement the skillset of these Committees and Jeanne will serve on the
Investment and Clinical Committees of the Company.

Ms Audrey Mothupi, a current independent non-executive director on the Board, will step
down from the Audit Committee with effect from 1 August 2022, to focus her commitments on
the other Board Committees that she serves on. The Board would like to thank Audrey for her
invaluable contribution to the Audit Committee during her tenure.

Advocate Mahlape Sello has been appointed as a member on the Social, Ethics and
Transformation Committee, with effect from 1 August 2022.

Changes to the Terms of Reference for the Nominations and Governance Committee
Shareholders and noteholders are advised that the Nominations and Governance
Committee’s terms of reference have been updated and the updated Terms of Reference will
be available at https://www.lifehealthcare.co.za/investor-relations/domestic-medium-term-
note-programme/.

Enquiries:
Joshila Ranchhod – Group Company Secretary
E-mail: joshilar@life.co.za

28 July 2022
Dunkeld

Sponsor and Debt Sponsor
RAND MERCHANT BANK (a division of FirstRand Bank Limited)

Date: 28-07-2022 11:10:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.

Share This Story